Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 2
---
 337,711,000,000 Ordinary Shares

Up to 3,377,110 American Depositary Shares Representing 337,711,000,000 Ordinary Shares Underlying the Pre-Funded Warrants

Up to 50,656,650 American Depositary Shares Representing 5,065,665,000,000 Ordinary Shares Underlying the Series L Warrants (which contain a “zero cash exercise price” option)

Up to 2,532,825 American Depositary Shares Representing 253,282,500,000 Ordinary Shares Underlying the Placement Agent Warrants (which contain a “zero cash exercise price” option)

___________________</div>

This preliminary prospectus, or prospectus, relates to a best efforts
public offering of up to 3,377,110 Units, or Units, of Biodexa Pharmaceuticals PLC, a public limited company organized under the laws
of England and Wales, or the Company, each Unit consisting of (i) one American Depositary Share (representing 100,000 of our ordinary
shares, nominal value £0.000001 per share, or Ordinary Shares), or Depositary Shares, and (ii) one Series L warrant, or Series L
Warrant, to purchase one Depositary Share, at an assumed combined public offering price of $5.33 per Unit, based upon the closing price
of our Depositary Shares on the NASDAQ Capital Market on November 12, 2025, or otherwise acquire such greater number of Depositary Shares
as determined in accordance with the provisions of the Series L Warrant upon a “zero cash exercise price” option (as discussed
below).

Each Series L Warrant will be immediately
exercisable at an exercise price of 225% of the public offering price of each Unit in this offering and will expire two and a half (2.5)
years after the issuance date. The Series L Warrants also contain certain anti-dilution protections, certain mechanisms for cashless exercise
and contain a zero cash exercise price option, as well as certain reset provisions of the exercise price and the number of Depositary
Shares (represented by Ordinary Shares) underlying the Series L Warrants, as further described herein.

Under the “zero cash
exercise price” option of the Series L Warrants, during the period of 90 calendar days following the issue date of the Series L
Warrants, a holder of the Series L Warrant has the right to receive, without payment of any additional